Article title:

Impact of Breast Cancer on Body Image: A Systematic Review and Meta-Analysis

Author names:
Serenay Yazici Sarikaya [a,*], Rui Wang [a], Ann-Christin S. Kimmig [a], Sara Brucker [b], Markus Hahn [b], Anna Wikman [c] & Birgit Derntl [a,d,**]

Affiliations:
[a] Department of Psychiatry and Psychotherapy, Tübingen Center for Mental Health (TüCMH), University of Tübingen, Tübingen, Germany; [b] Department of Gynecology and Obstetrics, University of Tübingen, Tübingen, Germany; [c] Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden; [d] German Center for Mental Health (DZPG), Partner Site Tübingen, Tübingen, Germany.

Corresponding author:

[*] Corresponding Author: Department of Psychiatry and Psychotherapy, Tübingen Center for Mental Health (TüCMH), University of Tübingen, Tübingen Germany.

Email addresses: serenay.yazici.sarikaya@med.uni-tuebingen.de

[**] Corresponding Author: Department of Psychiatry and Psychotherapy, Tübingen Center for Mental Health (TüCMH), University of Tübingen, Tübingen Germany.

Email addresses: birgit.derntl@med.uni-tuebingen.de

ORCID

Serenay Yazici Sarikaya https://orcid.org/ **0000-0001-8891-827**

ABSTRACT

Purpose: Breast cancer is the most common cancer among women worldwide. Although treatment is essential and often life-saving, it can have profound consequences beyond physical health, particularly for psychological well-being and body image. This study aimed to systematically review and synthesize the existing evidence on how breast cancer and its treatment affect body image in women.

Methods: We conducted a systematic search of four major electronic databases for peer-reviewed studies published up to 2025. In total, 41 studies met the inclusion criteria for the systematic review, and 24 were included in the meta-analysis. Standardized mean differences (SMDs) with 95% confidence intervals were calculated using a restricted maximum likelihood model. Analyses were performed in JAMOVI, and heterogeneity was assessed using Cochran's Q and I² statistics. The review was registered in PROSPERO (CRD42024503033).

Results: Females with breast cancer reported significantly lower body image scores than healthy controls (ES = -1.02). Furthermore, body image scores declined from pre-treatment to during treatment (ES = -0.45). Mastectomy was associated with poorer body image compared to breast-conserving therapy (ES = -1-11).

Conclusion: Although medically essential, breast cancer treatment can adversely affect body image. Integrating body image support into treatment plans is crucial for promoting the overall health and quality of life of females diagnosed with breast cancer.

Keywords: Breast cancer, Body image, Women's health, Women's mental health, Systematic review, Meta-analysis

1. BACKGROUND

Breast cancer (BC) was the most frequently diagnosed cancer type among females worldwide (1–3), with more than 2 million new cases reported in 2020 (4) and over 300.000 additional cases recorded only in the USA in 2024 (5). Although breast cancer treatment is life-saving and essential, the disease and its treatment undeniably affect multiple aspects of the well-being of females with BC (see review: 69), including mental and physical health, as well as body image (6–8). All of these factors can collectively influence and worsen the quality of life of afflicted females (10–15).

Body image refers to the mental representation individuals form of their body, reflecting how they perceive their own physical appearance (16), and related concerns (17). It has both personal and interpersonal dimensions, involving (dis)satisfaction with one's physical appearance, (diminished) femininity, and (compromised) body integrity, as well as beliefs about how others perceive oneself (18,19). BC diagnosis and its treatment can lead to a wide range of body-related side effects, including breast loss, changes in breast appearance, scarring, hair loss, weight and appetite fluctuations, treatment-induced menopause, potential infertility, sleep disturbances, musculoskeletal issues, and sexual health concerns such as reduced libido, vaginal dryness, and pain, all of which may negatively affect body image (17,20–23). Altered body image is a significant psychosocial concern for females with BC, with studies consistently reporting poorer body image compared to healthy controls (17,24–28). Ongoing treatment, in particular, has been linked to further declines in body image when comparing patients before and during treatment (29–32).

Given the pivotal role of treatment in shaping body image, it is essential to consider how different treatment modalities may differentially affect female's perceptions of their bodies. Depending on tumor biology and cancer stage, treatment may include systemic therapy, radiotherapy, and surgery – either breast-conserving therapy (BCT) or mastectomy (MX) While BCT involves removal of the tumor and some surrounding tissue, MX entails complete removal of the breast. Studies comparing their effects on body image have yielded mixed results: some show more favorable outcomes with BCT (33–37), others report no significant differences (38,39), and one study even observed better body image in MX patients (26).

Recent literature has emphasized the need to advance our understanding of psychological adjustment in breast cancer by moving beyond symptom-specific or phase-limited perspectives toward integrative frameworks that capture mental health trajectories across the entire continuum of care. One such framework is the recently proposed Breast Cancer Psychological Integrative Phasic Model, which synthesizes existing theoretical and empirical work into a phase-sensitive structure encompassing screening, diagnosis, treatment, survivorship, and recurrence (43). Each phase is marked by distinct psychosocial challenges and associated symptom profiles, ranging from anxiety and trauma-related distress to depression and fear of recurrence, highlighting how mental health evolves in parallel with medical treatment. This phasic perspective provides a valuable lens for examining body image disturbances, which often arise or intensify during treatment and survivorship. Rather than treating body image problems in isolation, the model situates them within a broader constellation of psychological responses shaped by temporal and structural dynamics across the cancer trajectory.

Overall, BC and its treatment modalities appear to lead to mixed results regarding body image, and a quantitative evaluation of the effects of disease, different treatment modalities, and treatment durations is still lacking. To our knowledge, this is the first systematic review and meta-analysis to simultaneously examine body image changes in these three domains: 1) disease effect, 2) treatment effect, and 3) treatment modality. Therefore, a systematic review and meta-analysis of the existing data on body image in females with BC is required to offer a comprehensive overview of the field. This will help guide future studies, directing scientific inquiry to explore any gaps in understanding and improve knowledge for physicians, patients, and their relatives.

The aim of the study is to investigate:

1) Effect of disease (females with BC vs. healthy controls): How does the body image of females with BC differ from that of healthy individuals?

2) Effect of treatment (before vs. during): What changes occur in the body image of females with BC when comparing the before to the ongoing treatment phase?

3) Treatment modality (MX vs. BCT): How do body image perceptions, including both negative and positive aspects, vary between females with BC undergoing mastectomy (MX) and those receiving breast-conserving therapy (BCT)?

2. METHODS

A systematic review and meta-analysis on body image in females with BC was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement (40). Prior to performing this study, a review protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (Registration No. CRD42024503033; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024503033).

2.1 Search strategy

Published studies up to 2025 were searched in PubMed, APA PsycINFO, CINAHL, and Web of Science Core Collection by Uppsala University Library. The following search terms were used: ("breast neoplasm*" OR "breast cancer*" OR "breast tumor*" OR "breast carcinoma*" OR "mammary cancer*" OR "mammary carcinoma*" OR "mammary tumor*" OR "mammary neoplasm*") AND ("female*" OR "girl*" OR "woman*" OR "women*") AND ("body image" OR "body acceptance" OR "body schema" OR "body dissatisfaction" OR "body esteem" OR "body image disturbance*" OR "body checking" OR "dysphoria" OR "physical self" OR "self-image" OR "body shame" OR "body perception" OR "body satisfaction" OR "body appreciation")

2.2 Eligibility criteria

Articles were considered eligible if they met the following inclusion criteria: (1) original research; (2) measuring body image as a primary outcome variable (a full list of questionnaires is provided in Supplementary Table 1); (3) fully accessible text; (4) studies on female breast cancer patients vs. healthy controls, baseline vs. ongoing breast cancer treatment process, MX vs. BCT; (5) studies only cover current female breast cancer patients with no metastasis and no breast reconstruction; (6) observational studies. Articles were excluded when they met one of the following criteria: (1) non-peer-reviewed manuscripts, non-research articles, non-English articles, meeting abstracts; (2) studies on physical, psychological, or psychosocial intervention/counseling; (3) studies on couple-based issues; (4) studies on unmet needs; (5) lack of a control group.

This study included only females with non-metastatic BC to increase validity and consistency, as metastatic BC occurs when cancer has spread beyond the breast, indicating an advanced stage, and

is often associated with severe symptoms such as fatigue and pain, which can exacerbate treatment side effects (41,42).

2.3 Study selection and Data extraction

Two reviewers (SYS and RW) independently extracted relevant data from the included studies. Any discrepancies were identified and resolved through consensus in consultation with co-authors MH and BD. The following information was extracted for all articles: (1) Publication information (title/author/year/journal); (2) Study characteristics (aim/study design/data collection/mean and standard deviation); (3) Participants (sample size/age/treatment/symptom); (4) Outcomes (instrument-related data, mean results).

In the meta-analysis, mean and standard deviation values were directly extracted from the original tables in the studies. Transforming scale orientations (e.g., for positive vs. negative body image) was avoided to preserve data integrity, as such transformations could compromise the original meaning and reliability of the data reported by the primary sources. Various body image-related questionnaires were included in the meta-analysis (see Supplementary Table 1). Positive body image was defined by higher scores on relevant questionnaires, whereas negative body image was indicated by higher scores on specific questionnaires. As such, two separate meta-analyses were conducted for the comparison of MX vs BCT groups.

If any articles included two groups/subgroups, data were extracted separately for each group/subgroup. When the study measured body image repeatedly (more than two times) in a longitudinal fashion, we included only two distinct measurement time points, each with a larger number of participants, to minimize the risk of result duplication and ensure the robustness of our analysis. When multiple studies included the same sample, only the study with the largest sample was included to avoid duplication of participants. Articles that described body image but lacked quantitative data – despite attempts to obtain this information from the authors via email – were included in the descriptive systematic review rather than the quantitative meta-analysis.

2.4 Quality assessment

2.4.1 Assessment of risk of bias

The risk of bias for each included paper was evaluated independently by two reviewers using the Newcastle-Ottawa Scale (NOS) (43) and the Risk Of Bias in Non-randomized Studies of

Interventions Scale (ROBINS-I) (44) based on the study characteristics. The NOS is a straightforward quality assessment tool specifically for non-randomized cohort and case-control studies, focusing on three elements: selection of study groups, comparability between groups, and allocation of the exposure or outcome of interest. Assessment quality is categorized as low (0–4), moderate (5–7), or high (8–10). For some studies, it was not possible to apply the NOS, in these cases the ROBINS-I tool was applied. The ROBINS-I is a comprehensive tool suitable for various study designs, offering a nuanced quality assessment through detailed questions on potential biases, such as those in reported outcomes and intervention classification. Specifically designed for non-randomized intervention studies, ROBINS-I evaluates seven bias elements: confounding, participant selection, intervention classification, deviations from intended interventions, missing data, outcome measurement, and selection of reported outcomes. Quality is rated in four categories: low, moderate, serious, and critical.

2.4.2 Publication bias

The publication bias was assessed by visual inspection of funnel plots and Egger's regression test for asymmetry (45) using the JAMOVI (2.3.38) software (46). Significant publication biases were identified by p-values lower than 0.05.

2.5 Statistical analysis

We analyzed the differences in body image between (1) females with BC vs. healthy controls, (2) females with BC before vs. during treatment, and (3) females with BC who had undergone MX vs. BCT. The standardized mean differences and their 95% confidence intervals (CI) were calculated using a Random Effects (RE) model with between-study variance estimated via Restricted Maximum Likelihood (REML) (47), due to substantial heterogeneity in clinical samples and methodological approaches between studies. Mean, standard deviation and sample size were provided from the included studies or corresponding authors. All statistical analyses were performed using JAMOVI (version 2.3.38) (46), and the alpha level was set at $p<0.05$. Forest plots present the overall effect size estimates along with their corresponding 95% confidence intervals. The number of included studies in each analysis was reported by "k" and effect size was reported by "μ". Heterogeneity among the studies in each analysis was evaluated using Cochran's Q and Higgins' I^2 statistics (43). A threshold of 25%, 50%, and 75% was used to differentiate between low, medium, and high heterogeneity.

3. RESULTS

3.1 Literature retrieval results and study characteristics

The database search initially yielded a total of 6738 studies. Based on the titles and abstracts, the first screening excluded 3904 studies and retained 363 studies for further evaluation. After the full-text screening, 322 studies were excluded. See Fig 1 for a flow chart of article selection following the PRISMA 2020 guidelines.

Ultimately, 41 studies were included in the final analysis of this study. The included studies were published between 1988 and 2025. Based on the availability of body image scores, 24 body image-related studies contained adequate data for quantitative synthesis in the meta-analysis. Five reported differences between females with BC and controls, ten compared before vs. during treatment, six compared MX vs. BCT in the negative body image direction, and eight estimated MX vs. BCT in the positive body image direction. Some studies contributed data to multiple meta-analyses due to their design and reporting structure. Specifically, certain studies included both cross-sectional comparisons (e.g., females with breast cancer vs. healthy controls) and longitudinal assessments (e.g., pre-treatment vs. during treatment) or provided subgroup analyses based on surgical type (e.g., MX vs. BCT). For instance, a single study might compare females with BC to healthy controls while also reporting within-group changes over time among the breast cancer cohort, thereby contributing to a second meta-analysis. There were 4 studies that were included in more than one meta-analysis. Those studies marked in Table 1-3 to indicate which data were used for which meta-analysis. These studies included 6872 females with BC and 398 healthy controls. The general characteristics of the 41 included studies are presented in Tables 1-3 with the studies that could not be included in the meta-analysis highlighted with asterisks.

The geographic distribution of the studies included in the systematic review and meta-analysis is depicted in a pie chart (Fig. 2), highlighting potential cultural influences on body image among females with BC.

Fig 1. PRISMA flow diagram of the study search and selection process.

BCP vs HC			
Region	**Country**	**Percentage of the Participants**	**Percentage of the Countries**
Asia	India	10.6	11.1
Europa	Belgium	9.9	11.1
	Greece	12.4	11.1
	Poland	28.2	22.2
	Spain	4.8	11.1
Middle East	Iran	28.5	22.2
USA	USA	5.5	11.1
Before vs During Treatment			
Region	**Country**	**Percentage of the Participants**	**Percentage of the Countries**
Africa	Ethiopia	8.6	7.1
Asia	Bangladesh	14.8	7.1
Europa	Belgium	4.8	7.1
	France	6.4	7.1
	Sweden	4.4	7.1
	Spain	10.6	7.1
Middle East	Lebanon	7.1	7.1
	Turkey	15.3	7.1
North America	Canada	1.4	7.1
South America	Brazil	16.5	21.4
USA	USA	10.0	14.3
MX vs BCT			
Region	**Country**	**Percentage of the Participants**	**Percentage of the Countries**
Asia	China	4.5	4.5
	India	13.6	13.6
	Sri Lanka	4.5	4.5
Europa	Belgium	4.5	4.5
	Germany	4.5	4.5
	Italy	4.5	4.5
	Norway	4.5	4.5
	Poland	9.1	9.1
	Portugal	4.5	4.5
	Spain	4.5	4.5
Middle East	Iran	4.5	4.5
	Turkey	13.6	13.6
Oceania	Australia	4.5	4.5
USA	USA	18.2	18.2

Fig 2) The table illustrates the percentage of countries and samples of each country included in the study

3.2 Meta-analyses & Qualitative analyses

3.2.1 Comparison of body image in Females with BC vs. Healthy Controls

Nine articles were identified targeting this comparison and were published between 1999 to 2023. Among them, four studies lacked quantitative body image data and thus were included in the systematic review (see Table 1 for their characteristics).

Five studies were included in this meta-analysis and reported data from 469 females with BC and 479 healthy controls (with three studies using age-matched controls). They were conducted in Belgium, the USA, Spain, Iran, and India (17,26–28,48).

Compared to healthy controls, females with BC had a significantly worse body image score (k = 5, μ = -1.02 95 %CI [-1.53, -0.51], p < 0.001, see Fig 3). This finding presented a large effect size in the negative direction (ES = -1.02). The heterogeneity between studies was high (I^2 = 87.23%, p < 0.001).

Fig 3: Forest plot of body image scores comparing values from females with breast cancer (BCP) and healthy controls (HC). Note. *** marks significant group difference with p < 0.001. Abbreviations: RE= Random Effects

3.2.1.2 Qualitative analysis (females with BC vs. healthy controls). Studies report significantly higher levels of body dissatisfaction in females with BC than in healthy controls (24,25,49). Additionally, lower body acceptance was shown in females with BC compared to healthy controls (50).

3.2.2 Comparison of body image before vs during treatment

Fourteen articles were identified targeting this comparison and were published between 1998 to 2023. Among them, four studies lacked quantitative body image data and thus were included only in the systematic review (see Table 2 for their characteristics).

Ten studies were included in this meta-analysis reporting data from 1262 females with BC before treatment and 1245 females with BC during treatment. The studies were conducted in Belgium, Turkey, Brazil (three studies), Sweden, Lebanon, Spain, the USA and Bangladesh (48,51–59).

Comparing body image data before vs during treatment, the meta-analysis revealed that patients had significantly higher body image before the start of treatment than during treatment (k = 13 μ = 0.449, 95 %CI [-0.83, -0.07], p = 0.019, see Fig 4). This finding presented a small to moderate negative effect size (ES = -0.45). The heterogeneity between studies was high (I^2 = 95.04%, p < 0.001).

Fig 4: Forest plot of body image for the comparison between before vs. during treatment. Note. Treatment modalities are included in this forest plot. MX = mastectomy, BCT = breast-conserving therapy, * marks significant group difference with $p < 0.05$ Abbreviations: RE= Random Effects

3.2.2.1 Qualitative analysis (Before vs. during treatment). Three additional studies show that females with BC have a negative body image during treatment than before treatment (30–32). However, one study (60) reported no significant change in body image before vs. during breast cancer treatment.

3.2.3 Comparison of MX vs BCT- negative and positive direction

Twenty-two articles were identified targeting this comparison and were published between 1998 to 2023. Among them, eight studies lacked quantitative body image data and thus were included only in the systematic review (see Table 3 for their characteristics).

Fig 5a&b: a) Forest plot of negative body image for the comparison between mastectomy (MX) and breast conservative therapy (BCT) Note. Negative body image refers to a person's dissatisfaction with their physical appearance or the way they perceive their body, * marks significant group difference with p < 0.05. b) Forest plot of positive body image for the comparison between mastectomy (MX) and breast conservative therapy (BCT). Note. Positive body image means having a satisfactory and accepting attitude towards one's body and appearance. Abbreviations: RE= Random Effects

3.2.3.1 Meta-analysis of negative direction. Six studies were included in this meta-analysis that measured the negative direction of body image and relied on data from 677 BCT and 547 MX. They were conducted in Belgium, Iran, Portugal, Germany, Spain, and India (27,48,61–64).

Compared to the BCT group, the MX group had significantly higher negative body image (k = 6, μ = -1.105, 95 %CI [-2.01, -0.20], p = 0.016, see Fig 5a). This finding presented a large effect size in the negative direction (ES = -1.11). Again, the heterogeneity between studies was high (I^2 = 97.19%, p < 0.001).

3.2.3.2 Meta-analysis of positive direction. Eight studies were included in this meta-analysis that measured the positive direction of body image and reported data from 809 BCT and 445 MX. Studies were conducted in India (two studies), Poland (two studies), Sri Lanka, Australia, and the USA (two studies) (57,65–71).

The meta-analysis revealed no significant difference between the BCT group and MX group, i.e., there was no group difference in terms of having a satisfactory and accepting attitude towards body image and appearance (k = 8, μ = 0.231, 95 %CI [-0.14, 0.60], p = 0.216, see Fig 5b). The heterogeneity between studies was high (I^2 = 88.02%, p < 0.001).

3.2.3.3 Qualitative analysis MX vs. BCT. Six additional studies indicate that females with BC treated with BCT report higher body image than those in the MX group (33–37,72). However, Kraus et al. (26) found greater body image satisfaction in the MX group, while two other studies did not report a significant difference between the BCT and MX groups in either a positive (38) or negative (39) direction.

3.3 Risk of bias

The risk of bias was assessed using NOS and ROBINS-I (see Tables 1-3). Out of the twenty-five studies assessed by NOS, four were determined to be high quality (8-10), sixteen were of moderate quality (5-7) and five were judged as low quality (0-4) based on the NOS criteria. Out of the fifteen studies assessed by ROBINS-I, twelve were determined to be of high quality, and three were of moderate quality based on the ROBINS-I criteria.

3.4 Publication bias

Publication bias was examined for all analyses of body image. The Egger's tests were not significant for any of the analyses: females with BC vs. HC (k = 5, value = 1.781, p = 0.075),

before vs during treatment (k = 13, value = 0.373, p = 0.709), MX vs BCT-negative (k = 6, value = 1.118, p = 0.263), and MX vs. BCT positive (k = 8, value = -0.471, p = 0.638) indicating no evidence for publication bias in these analyses.

4. DISCUSSION

In this study, we conducted a systematic review and meta-analysis to comprehensively examine the effects of BC and its treatments on body image. While breast cancer treatment is both life-saving and essential, it can have a significant impact on body image. Specifically, we addressed three key research questions: 1) How does the body image of females with breast cancer (BC) compare to that of healthy controls, 2) How does the body image of females with BC change before vs during treatment, and 3) How does body image differ between patients undergoing mastectomy (MX) and breast-conserving therapy (BCT), considering both negative and positive aspects?

4.1 Females with BC vs. Healthy controls

The meta-analysis examined body image differences between females with BC and healthy controls, revealing significant body image dissatisfaction among females with BC. Similarly, qualitative analysis of studies included in the systematic review demonstrated the same pattern. Hence, the literature consistently shows that females with BC experience higher levels of body image dissatisfaction, body image-related problems, and lower body acceptance compared to females without BC (10,18,24,25,27,28,49,50). This negative body image may be attributed to treatment-related changes such as weight gain, hair loss, breast loss, and scarring, all of which can adversely affect body image (27). Females with BC often perceive their bodies as a source of negative emotions, leading to lower self-esteem and difficulties in daily life (50), and these factors contribute to reduced body acceptance and more pronounced body image alterations. Both our findings and existing literature consistently show a strong link between poorer body image outcomes and the effects of cancer treatments, including chemotherapy, radiation therapy, endocrine therapy, and surgery. Meta-analysis is essential in uncovering deeper insights, as it not only consolidates evidence across studies but also helps address gaps and variability in the current research. This approach ensures a more thorough and reliable understanding of these treatment effects.

Nowadays, various types of treatments are chosen based on factors such as tumor size, cancer stage, and patient's condition. These treatments have many common side effects but also unique

ones. All of them affect body image, be it hair loss from chemotherapy, loss of fertility from tamoxifen therapy, or loss of a breast from mastectomy, which can negatively impact femininity, motherhood. Importantly, the impact on body image frequently extends well beyond the active treatment phase. Research indicates that many females with BC continue to experience persistent, or even increased body dissatisfaction during survivorship, as psychological adaptation often lags behind physical healing (73). Body image remains dynamic after treatment, influenced by enduring physical changes as well as emotional and social factors (74).

Psychosocial interventions have shown promise in supporting this adjustment, especially when aligned with individual characteristics and treatment experiences. A recent systematic review has shown that various interventions including cognitive behavioral therapy, mindfulness-based programs, self-compassion writing exercises, and body image–focused group therapies, can effectively reduce negative body image and promote positive aspects such as body appreciation and acceptance (75). For instance, programs like "Accepting your Body after Cancer" and guided imagery sessions have been shown to alleviate distress and enhance psychological resilience in females with BC (75,76). Tailoring these interventions to individual characteristics, cancer stage, and cultural background can further increase their relevance and impact. Embedding such strategies into clinical pathways from diagnosis through survivorship may help bridge the gap between research and practice, ultimately improving the psychological well-being and quality of life of females with BC.

Body image has psychosocial dimensions that are shaped by social norms and culture (77). Research indicates that social norms significantly influence cancer-related perceptions in females with BC, often leading to negative body image (78). Anagnostopoulos and Myrgianni (24) report that in Western cultures, women's bodies are highly valued, with breasts playing a crucial role in both gender identity and overall body integrity. Our systematic review and meta-analysis included studies not only from Western countries but also from regions such as the Middle East and Latin America (see Figure 2). This highlights the global impact of breast cancer on body image, drawing on data from diverse cultural contexts rather than focusing solely on a Western perspective. Although subgroup analyses to directly compare cultural differences were not conducted, the inclusion of studies and participants from various countries provides valuable insights into potential variations across populations. This multicultural approach broadens the understanding of

body image issues beyond the confines of Western culture, offering a more comprehensive and inclusive perspective in the field.

Emerging evidence suggests that culture not only contextualizes but also actively shapes how females experience body image following breast cancer. Yoo et al. highlight the role of sociocultural factors (such as education, economic background, and societal expectations) as key influences on body image distress in individuals with cancer (79). A recent systematic review further underscores that appearance-related norms, gender roles, and cultural values related to femininity can shape coping mechanisms and perceptions of bodily change (80). For instance, in collectivist societies, physical integrity may be closely tied to familial or marital roles, potentially intensifying body image concerns, whereas in individualistic societies, self-presentation and autonomy may be more strongly emphasized. These dynamics suggest that cultural context can act as a moderator in the relationship between cancer treatment and body image outcomes. Future meta-analyses should examine these differences systematically, using culturally sensitive measures and conceptual frameworks.

Puberty, pregnancy, and menopause are crucial hormonal transition phases in a female's life, each marked by physical changes and symptoms that can profoundly affect body image (81). Importantly, BC may co-occur with all of these transition periods (82–84), adding complexity to simple comparisons of patients with healthy controls. Therefore, examining body image during these transitions and exploring the experiences of females with BC in these phases, is crucial to account for possible variability in body image perceptions among different groups of females with BC.

4.2 Treatment effects

The meta-analysis evaluated potential changes in body image before vs. during treatment, mainly including data from studies on chemotherapy (n=4), radiotherapy (n=3), and surgery (n=7). The analysis confirmed that before the start of treatment, females with BC had a significantly higher body image scores, i.e. more positive body image, than during treatment (26,30–32,48,52,58,59,85). In terms of different treatment modalities, studies have shown a significant decrease in body image in females with BC undergoing chemotherapy (86), radiotherapy (53), and post-surgery (54,58). Thus, independent of treatment modality, a decrease in body image was

reported. These changes may be attributed to factors such as hair and breast loss, weight fluctuations, and scarring associated with the various treatment approaches (27).

Interestingly, El Haidari et al. (55) observed that married females with BC in Lebanon experienced a significant improvement in body image one day after breast-conserving surgery. Authors speculate that marital status may positively influence body image perceptions after surgery, possibly due to increased emotional resilience or supportive relationship dynamics within Lebanese culture (55).

A qualitative analysis of the studies included in the systematic review revealed varying findings: while some studies (30–32) supported the meta-analysis results, others found no significant differences in body image between the before and during treatment periods (57,60). This inconsistency may be explained by a shift in focus from physical appearance to survival concerns during treatment. Depending on patient characteristics, they may prioritize different factors affected by BC, such as physical appearance, loss of fertility, unhealthiness, or high responsibilities in their lives (57). Another possible reason is that in these females with BC, body image is not affected by the side effects of treatment, but rather by the impact of being diagnosed with BC (39,67). For this reason, changes in body image need to be assessed carefully and external factors should be taken into account.

4.3 Treatment modality (negative & positive direction)

MX and BCT are two primary treatment options for breast cancer (BC) (87). This meta-analysis investigated the differences in body image between females with BC who underwent MX and those who had BCT. It was hypothesized that the various effects of these two different treatment modalities on the breast, such as scarring or complete breast removal, affect body image differently. It was expected that MX would have a more negative effect on body image compared to BCT. The results indicate that MX is associated with significantly greater negative body image than BCT. However, in terms of the positive aspects of body image, no significant group differences were found. Recent literature presents inconsistent findings regarding body image following these two treatment options: while several studies indicate that females with BC who underwent MX report worse body image than those undergoing BCT (24,34–37,61,62,64,69,71,72,88), others showed no significant difference (38,39,65,67). Previous studies

observed greater body stigma (89) and greater alteration to their body image (36,90) in the MX group. Studies have shown that the MX group faces challenges with clothing and overall appearance, as well as body shame due to the loss of their breast(s) (91,92), which may contribute to greater body concerns and alteration.

Conversely, Kraus (26) found that females with BC who underwent MX reported higher body image satisfaction compared to those who underwent BCT. The author suggested that, in life-threatening situations following a BC diagnosis, physical appearance may become less significant, and the MX group might experience a sense of relief from the cancer diagnosis, which could mitigate concerns about body image despite the loss of their breast(s) (26). While this interpretation provides valuable insights, it must be viewed with caution due to the small sample size in the study (MX = 15, BCT = 16) conducted in 1999. Furthermore, since the study was conducted over two decades ago, social perspectives, cultural attitudes, and advancements in treatment modalities may have significantly evolved, potentially influencing body image experiences differently in contemporary populations. This is particularly relevant considering that BCT techniques were not widely adopted until the mid-1990s, and the quality of these procedures has improved over time. It is also important to note that the studies evaluating BCT are not randomized, which could affect the reliability of the findings.

Furthermore, several studies suggest no significant differences in body image between patients undergoing MX or BCT (38,39,65,67). This may be due to individual differences and personal beliefs of females with BC, suggesting that body image concern may be influenced more by the cancer itself than by the type of treatment received (38,39,65,67). Furthermore, the lack of significant differences in body image outcomes between these two types of surgery underscores the importance of prioritizing body image concerns for all patients, regardless of the surgical approach (50,93).

Moreover, the mixed findings regarding the effects of BC and its treatment on body image highlight the need for further research that considers sociodemographic factors. Education level, marital status, age, treatment modalities, and patients' own perspective on their illness may play an important role in their body image and perspective on cancer. Additionally, raising awareness about breast cancer, its treatment, and its potential impact on body image is essential to support patients in managing these challenges effectively. Providing psychoeducation to help patients

manage potential side effects can improve their understanding of body image issues associated with changes in breast shape or loss after surgery and their ability to cope with BC (94,95).

This systematic review and meta-analyses are the first to offer a comprehensive multi-parameter quantitative synthesis of the impact of BC on body image. Our rigorous inclusion criteria and standardized review process, in accordance with following the PRISMA guidelines, contribute to the robustness and reliability of our findings.

4.4 Study Limitations

Nonetheless, several limitations should be considered when interpreting these results. First, the number of studies included in some analyses was relatively small, particularly in the comparison of body image between breast cancer patients and healthy controls (n=5). Second, the lack of differentiation between participants based on treatment duration (e.g., days, months, or years) is another limitation. Future studies should consider categorizing participants into multiple groups based on treatment duration to allow for a more nuanced understanding of the effects of treatment. Third, while most studies comparing females with BC to healthy controls collected data post-treatment, two studies included both pre- and post-treatment patients without distinguishing between these subgroups in their analyses or conclusions. This methodological limitation may have obscured potential differences in body image experiences across treatment stages. Additionally, the wide period of the studies, as well as advances in surgical techniques and therapies, may introduce variability in the results. Breast-conserving surgery became widespread in the mid-1990s, with high-quality procedures becoming standard only after 2000. Poor surgical quality before 2000 likely influenced body image outcomes, but because only one study before 2000 included both MX and BCT, sub analysis was not possible. Lastly, since surgical studies are not randomized, postoperative satisfaction may not be differentiated without any bias.

The considerable heterogeneity observed in all our meta-analyses can be attributed to several interrelated factors, including differences in patient characteristics, treatment protocols, and study methodologies across the included studies. Variability in age, disease stage, cultural background, and psychosocial factors likely influenced how body image was perceived and reported by participants. Additionally, treatment-related differences—such as variations in the type and timing of surgery, chemotherapy, and radiotherapy—may have further contributed to inconsistencies in body image outcomes. Methodological factors, including the use of diverse body image

assessment tools (e.g., different questionnaires), study designs (e.g., cross-sectional or longitudinal), and sample sizes, may also play a significant role in driving heterogeneity. These variations might likely underlie the observed differences in body image outcomes among BC patients, resulting in significant heterogeneity across studies.

4.5 Clinical Implications and Future Direction

This systematic review and meta-analysis offer valuable insight into body image changes associated with BC and its treatment, providing a detailed scientific perspective on these effects.

Recognizing the complex effects of breast cancer and its treatment allows both patients and healthcare providers to anticipate the body image challenges that may arise throughout the BC treatment process. Providing healthcare providers with this insight is essential, as it enables them to support patients more effectively by integrating body image considerations into patient care. The findings can help identify the potential impact of BC and its treatments on body image, which underscores the need to incorporate body image considerations into psychoeducation and treatment plans, ultimately improving patient support and quality of life. By proactively addressing these concerns, healthcare providers can promote emotional resilience, support mental health, and improve the quality of life for females with BC, contributing to a more comprehensive care experience.

Future research should reduce heterogeneity by standardizing assessment tools, stratifying participants by key variables, and harmonizing protocols to enhance comparability and deepen understanding of the relationship between breast cancer, its treatments, and body image.

5. CONCLUSION

This meta-analysis offers valuable insight into body image changes associated with BC and its treatment, providing a detailed scientific perspective on these effects. The findings demonstrate that females with BC experience significantly poorer body image compared to females without BC. Additionally, BC patients report better body image before starting treatment than ongoing treatment phases, suggesting that treatment itself contributes to body image concerns. Furthermore, among females with BC, those who undergo MX tend to report worse body image outcomes compared to those receiving BCT, highlighting the differential impact of treatment types on body perception. Although BC treatment is essential, its impact on body image remains a

significant challenge. This review highlights the need for comprehensive treatment that addresses these concerns to improve women's overall well-being and quality of life.

List of abbreviations

BC Breast Cancer

BCT Breast Conserving Therapy

CI confidence intervals

HC Healthy Controls

MX Mastectomy

NOS Newcastle-Ottawa scale

PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PROSPERO International Prospective Register of Systematic Reviews

RE Random Effects

REML Restricted Maximum Likelihood

ROBINS-I Risk Of Bias in Non-randomized Studies of Interventions Scale

Declarations

Ethics approval and consent to participate:

Not applicable.

Consent for publication:

Not applicable.

Competing interests:

The authors declare no competing interests

CRediT authorship contribution statement

Serenay Yazici Sarikaya: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft, Writing – review & editing. **Rui Wang:** Conceptualization, Validation, Writing – review & editing. **Ann-Christin S. Kimmig:** Conceptualization, Validation, Writing – review & editing. **Sara Brucker:** Conceptualization, Validation, Writing – review & editing. **Markus Hahn:** Conceptualization, Validation, Writing – review & editing. **Anna Wikman:** Conceptualization, Methodology, Resources, Supervision, Validation, Writing – review & editing. **Birgit Derntl:** Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Writing – review & editing.

Acknowledgments

This work was performed as part of the International Research Training Group, "Women's Mental Health Across the Reproductive Years" (IRTG 2804). The IRTG 2804 is funded by the German Research Foundation (DFG). The grant number is: GRK 2804/1. The authors would like to thank all those who provided additional information for this meta-analysis.

Funding

This work was supported by grants from the Deutsche Forschungsgemeinschaft (IRTG2804; Women's Mental Health Across the Reproductive Years). The funders were not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.

Conflict of Interest Statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Availability of data and materials

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

References

1.	Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast. 2022 Dec 1;66:15–23. doi:10.1016/j.breast.2022.08.010

2.	James R, McCulley SJ, Macmillan RD. Oncoplastic and reconstructive breast surgery in the elderly. Br J Surg. 20150218th ed. 2015 Apr;102(5):480–8. Located at: 25689974. doi:10.1002/bjs.9733

3.	Jassim GA, Whitford DL. Quality of life of Bahraini women with breast cancer: a cross sectional study. BMC Cancer. 2013/04/30 ed. 2013 Apr 28;13:212. Located at: 23622020. doi:10.1186/1471-2407-13-212

4.	Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778–89. doi:10.1002/ijc.33588

5.	Mallick S, Sharma CK. Evidence in Breast Cancer. Springer Nature; 2025. 532 p.

6.	Brunet J, Price J. A scoping review of measures used to assess body image in women with breast cancer. Psychooncology. 2021;30(5):669–80. Located at: cin20; 150206729. Language: English. Entry Date: 20210511. Revision Date: 20220502. Publication Type: Journal Article. doi:10.1002/pon.5619

7.	Falk Dahl CA, Reinertsen KV, Nesvold IL, Fosså SD, Dahl AA. A study of body image in long-term breast cancer survivors. Cancer. 2010 Aug 1;116(15):3549–57. Located at: 20564138. doi:10.1002/cncr.25251

8.	Guedes TSR, Dantas de Oliveira NP, Holanda AM, Reis MA, Silva CP, Rocha e Silva BL, et al. Body Image of Women Submitted to Breast Cancer Treatment. Asian Pac J Cancer Prev. 20180625th ed. 2018 Jun 25;19(6):1487–93. Located at: 29936719. doi:10.22034/apjcp.2018.19.6.1487

9.	Prates ACL, Freitas-Junior R, Prates MFO, Veloso MF, Barros NM. Influence of Body Image in Women Undergoing Treatment for Breast Cancer. Rev Bras Ginecol Obstet. 2017;39(4):175–83. Located at: rayyan-1124869977. doi:10.1055/s-0037-1601453

10.	Bakht S, Najafi S. Body image and sexual dysfunctions: comparison between breast cancer patients and healthy women. In: Vol. 5. Antalya, TURKEY; 2010. p. 1493–7. (Procedia Social and Behavioral Sciences). Located at: WOS:000287160900274. Available from: ://WOS:000287160900274 doi:10.1016/j.sbspro.2010.07.314

11.	Fatehi S, Maasoumi R, Atashsokhan G, Hamidzadeh A, Janbabaei G, Mirrezaie SM. The effects of psychosexual counseling on sexual quality of life and function in Iranian breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat. 2019/02/01 ed. 2019 May;175(1):171–9. Located at: 30701349. doi:10.1007/s10549-019-05140-z

12.	Luo F, Link M, Grabenhorst C, Lynn B. Low Sexual Desire in Breast Cancer Survivors and Patients: A Review. Sex Med Rev. 2022/04/13 ed. 2022 Jul;10(3):367–75. Located at: 35410784. doi:10.1016/j.sxmr.2022.02.001

13.	Tejeda S, Stolley MR, Vijayasiri G, Campbell RT, Estwing Ferrans C, Warnecke RB, et al. Negative psychological consequences of breast cancer among recently diagnosed ethnically diverse women. Psychooncology. 2017 Dec;26(12):2245–52. doi:10.1002/pon.4456

14.	Begovic-Juhant A, Chmielewski A, Iwuagwu S, Chapman LA. Impact of Body Image on Depression and Quality of Life Among Women with Breast Cancer. J Psychosoc Oncol.

2012;30(4):446–60. Located at: cin20; 104471255. Language: English. Entry Date: 20120809. Revision Date: 20200708. Publication Type: Journal Article. doi:10.1080/07347332.2012.684856

15.   Piot-Ziegler C, Sassi ML, Raffoul W, Delaloye JF. Mastectomy, body deconstruction, and impact on identity: A qualitative study. Br J Health Psychol. 2010;15(3):479–510. Located at: cin20; 105066213. Language: English. Entry Date: 20101029. Revision Date: 20200708. Publication Type: Journal Article. doi:10.1348/135910709X472174

16.   Schilder. The Image and Appearance of the Human Body [Internet]. 1935 [cited 2024 Aug 7]. Available from: https://www.taylorfrancis.com/books/mono/10.4324/9781315010410/image-appearance-human-body-paul-schilder

17.   Rasekh Jahromi A, Ranjbar A, Naseripour P, Rahmanian V, Jamali S. Body image and sexual function in women with breast cancer. Sex Relatsh Ther. 2022 Jul 11;1–11. doi:10.1080/14681994.2022.2097212

18.   Fobair P, Stewart S, Chang S, Bloom J. Body image and sexuality in women with breast cancer. Psychooncology. 2003 Jun;12(4):S105–S105. Located at: WOS:000183225400094

19.   Stokes R, Frederick-Recascino C. Women's Perceived Body Image: Relations with Personal Happiness. J Women Aging. 2003 Feb 1;15(1):17–29. doi:10.1300/J074v15n01_03 PubMed PMID: 12678183.

20.   Can G, Oskay Ü, Duran Z, Aydiner A, Saip P, Disci R, et al. Evaluation of Sexual Function of Turkish Women With Breast Cancer Receiving Systemic Treatment. Oncol Nurs Forum. 2008 May 23;35:471–6. doi:10.1188/08.ONF.471-476

21.   Cavalheiro JA, Bittelbrunn A, Menke CH, Biazús JV, Xavier NL, Cericatto R, et al. Sexual function and chemotherapy in postmenopausal women with breast cancer. BMC Womens Health. 2012/09/12 ed. 2012 Sep 11;12:28. Located at: 22963155. doi:10.1186/1472-6874-12-28

22.   Cornell LF, Mussallem DM, Gibson TC, Diehl NN, Bagaria SP, McLaughlin SA. Trends in Sexual Function After Breast Cancer Surgery. Ann Surg Oncol. 2017/06/01 ed. 2017 Sep;24(9):2526–38. Located at: 28560595. doi:10.1245/s10434-017-5894-3

23.   Safarinejad MR, Shafiei N, Safarinejad S. Quality of life and sexual functioning in young women with early-stage breast cancer 1 year after lumpectomy. Psychooncology. 2012/07/11 ed. 2013 Jun;22(6):1242–8. Located at: 22777952. doi:10.1002/pon.3130

24.   Anagnostopoulos F, Myrgianni S. Body Image of Greek Breast Cancer Patients Treated with Mastectomy or Breast Conserving Surgery. J Clin Psychol Med Settings. 2009 Dec;16(4):311–21. Located at: WOS:000270432800004. doi:10.1007/s10880-009-9176-5

25.   Izydorczyk B, Kwapniewska A, Lizińczyk S, Sitnik-Warchulska K. Characteristics of psychological resilience and body image in women in the early and late periods after mastectomy. Health Psychol Rep. 2019;7(1):32–47. Located at: rayyan-1124871634. doi:10.5114/hpr.2018.79996

26.   Kraus PL. Body image, decision making, and breast cancer treatment. Cancer Nurs. 1999;22(6):421–9. Located at: rayyan-1124870355. doi:10.1097/00002820-199912000-00004

27.   Montañés-Muro P, Martínez-Tomé M, García-Manzano G. Psychosocial Care Needs of Women with Breast Cancer: Body Image, Self-Esteem, Optimism, and Sexual Performance and Satisfaction. Health Soc Work. 2023;48(2):115–23. Located at: cin20; 163279514. Language: English. Entry Date: 20230428. Revision Date: 20230428. Publication Type: Journal Article. doi:10.1093/hsw/hlad001

28. Savani CD, Patel AH, Oswal RM. Body image concern, quality of life, and psychological reaction among breast cancer patients: A cross-sectional study in a tertiary care hospital of Western India. Ann Indian Psychiatry. 2023;7(1):47–53. Located at: rayyan-1124871610. doi:10.4103/aip.aip_166_22

29. Boquiren VM, Esplen MJ, Wong J, Toner B, Warner E, Malik N. Sexual functioning in breast cancer survivors experiencing body image disturbance. Psychooncology. 2015/04/29 ed. 2016 Jan;25(1):66–76. Located at: 25916689. doi:10.1002/pon.3819

30. Carver CS, Pozo-Kaderman C, Price AA, Noriega V, Harris SD, Derhagopian RP, et al. Concern about aspects of body image and adjustment to early stage breast cancer. Psychosom Med. 1998;60(2):168–74. Located at: rayyan-1124870378. doi:10.1097/00006842-199803000-00010

31. Laroche F, Perrot S, Medkour T, Cottu PH, Pierga JY, Lotz JP, et al. Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer A multicenter cohort study. PLoS ONE. 2017;12(11). Located at: APA PsycInfo; 2018-15325-001. doi:10.1371/journal.pone.0187165

32. Metcalfe KA, Cil TD, Semple JL, Li LD, Bagher S, Zhong T, et al. Long-Term Psychosocial Functioning in Women with Bilateral Prophylactic Mastectomy: Does Preservation of the Nipple-Areolar Complex Make a Difference? Ann Surg Oncol. 2015/07/26 ed. 2015 Oct;22(10):3324–30. Located at: 26208581. doi:10.1245/s10434-015-4761-3

33. Arikan F, Korukcu O, Kucukcakal A, Coskun HS. Determination of Self-Efficacy, Body Image and Sexual Adjustment of Women with Breast Cancer. Eur J Breast Health. 2020 Oct;16(4):282–9. Located at: WOS:000575221700010. doi:10.5152/ejbh.2020.5188

34. Fung KW, Lau Y, Fielding R, Or A, Yip AWC. The impact of mastectomy, breast-conserving treatment and immediate breast reconstructions on the quality of life of Chinese women. Anz J Surg. 2001 Apr;71(4):202–6. Located at: WOS:000169486400004. doi:10.1046/j.1440-1622.2001.02094.x

35. Schou I, Ekeberg Ø, Sandvik L, Hjermstad MJ, Ruland CM. Multiple predictors of health-related quality of life in early stage breast cancer Data from a year follow-up study compared with the general population. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2005;14(8):1813–23. Located at: rayyan-1124869163. doi:10.1007/s11136-005-4344-z

36. Spatuzzi R, Vespa A, Lorenzi P, Miccinesi G, Ricciuti M, Cifarelli W, et al. Evaluation of Social Support, Quality of Life, and Body Image in Women with Breast Cancer. Breast Care. 2016;11(1):28–32. Located at: WOS:000371791200006. doi:10.1159/000443493

37. Yilmazer N, Aydiner A, Ozkan S, Aslay I, Bilge N. A comparison of body image, self-esteem and social support in total mastectomy and breast-conserving therapy in Turkish women. Support Care Cancer. 1994;2(4):238–41. Located at: rayyan-1124868916. doi:10.1007/bf00365728

38. Alicikus ZA, Gorken IB, Sen RC, Kentli S, Kinay M, Alanyali H, et al. Psychosexual and Body Image Aspects of Quality of Life in Turkish Breast Cancer Patients: A Comparison of Breast Conserving Treatment and Mastectomy. Tumori J. 2009 Mar;95(2):212–8. doi:10.1177/030089160909500213

39. Yurek DL. Surgical treatment of breast cancer: Sexual self schema, stress reactions, and sexuality outcomes [Internet]. Vol. 59. ProQuest Information & Learning; 1998. Located at: APA PsycInfo; 1998-95014-204. Available from: https://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1998-95014-204&site=ehost-live

40.   Page M, Mckenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi:10.1136/bmj.n71

41.   Butt Z, Rosenbloom SK, Abernethy AP, Beaumont JL, Paul D, Hampton D, et al. Fatigue is the Most Important Symptom for Advanced Cancer Patients Who Have Had Chemotherapy. J Natl Compr Canc Netw. 2008 May 1;6(5):448–55. doi:10.6004/jnccn.2008.0036

42.   Palesh OG, Collie K, Batiuchok D, Tilston J, Koopman C, Perlis ML, et al. A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer. Biol Psychol. 2007 Apr;75(1):37–44. doi:10.1016/j.biopsycho.2006.11.002 PubMed PMID: 17166646; PubMed Central PMCID: PMC1894689.

43.   Wells, G. A., Shea, B., O'connell, D., Peterson, J., Welch, V., Losos, M., & Tugwell, P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. Clin Epidemiol. 2014.

44.   Corbett et al. Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool - Corbett - 2014 - Research Synthesis Methods - Wiley Online Library [Internet]. 2014 [cited 2024 Jul 30]. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/jrsm.1090

45.   Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sep 13;315(7109):629–34. doi:10.1136/bmj.315.7109.629 PubMed PMID: 9310563; PubMed Central PMCID: PMC2127453.

46.   Jamovi. (2022). The Jamovi Project, Version 2.3.

47.   PATTERSON HD, THOMPSON R. Recovery of inter-block information when block sizes are unequal. Biometrika. 1971 Dec 1;58(3):545–54. doi:10.1093/biomet/58.3.545

48.   Aerts L, Christiaens MR, Enzlin P, Neven P, Amant F. Sexual functioning in women after mastectomy versus breast conserving therapy for early-stage breast cancer: a prospective controlled study. Breast. 2014/08/02 ed. 2014 Oct;23(5):629–36. Located at: 25082211. doi:10.1016/j.breast.2014.06.012

49.   Bagheri M, Mazaheri M. Body Image and Quality of Life in Female Patients with Breast Cancer and Healthy Women. J Midwifery Reprod Health. 2015;3(1):285–92. Located at: rayyan-1124868005

50.   Jabłoński MJ, Streb J, Mirucka B, Słowik AJ, Jach R. The relationship between surgical treatment (mastectomy vs. breast conserving treatment) and body acceptance, manifesting femininity and experiencing an intimate relation with a partner in breast cancer patients. Psychiatr Pol. 2018/12/26 ed. 2018 Oct 27;52(5):859–72. Located at: 30584819. doi:10.12740/pp/91916

51.   Bahar S. Factors Affecting the Quality of Life in Breast Cancer Patients Undergoing Radiotherapy. Turk J Oncol. 2023. doi:10.5505/tjo.2023.3894

52.   Binotto M, Reinert T, Werutsky G, Zaffaroni F, Schwartsmann G. Health-related quality of life before and during chemotherapy in patients with early-stage breast cancer. Ecancermedicalscience. 2020/02/28 ed. 2020;14:1007. Located at: 32104209. doi:10.3332/ecancer.2020.1007

53.   Browall MM, Ahlberg KM, Persson LO, Karlsson PO, Danielson EB. The impact of age on Health-Related Quality of Life (HRQoL) and symptoms among postmenopausal women with breast cancer receiving adjuvant chemotherapy. Acta Oncol. 2008/01/23 ed. 2008;47(2):207–15. Located at: 18210297. doi:10.1080/02841860701621258

54.   Bueno JN, Haddad CAS, Rizzi S, Giron PS, Facina G, Nazario ACP. Evaluation of body image, quality of life, tactile sensitivity and pain in women with breast cancer submitted to surgical intervention. Rev Assoc Med Bras. 2018 Jun;64(6):530–6. Located at: WOS:000446592900009. doi:10.1590/1806-9282.64.06.530

55.   El Haidari R, Nerich V, Abou-Abbas L, Abdel-Sater F, Anota A. Pre-operative and early postoperative health-related quality of life of breast cancer woman: a Lebanese prospective study. BMC Womens Health. 2023;23(1):187. Located at: rayyan-1124871040. doi:10.1186/s12905-023-02348-6

56.   Marcelo Castro ESI, Lúcia Penteado Lancellotti C. Health-Related Quality of Life in Women with Breast Cancer Undergoing Chemotherapy in Brazil. Int J Gen Med. 2022/01/08 ed. 2021;14:10265–70. Located at: 34992441. doi:10.2147/ijgm.S343804

57.   Parker PA, Youssef A, Walker S, Basen-Engquist K, Cohen L, Gritz ER, et al. Short-term and long-term psychosocial adjustment and quality of life in women undergoing different surgical procedures for breast cancer. Ann Surg Oncol. 2007/06/19 ed. 2007 Nov;14(11):3078–89. Located at: 17574501. doi:10.1245/s10434-007-9413-9

58.   Rahman MM, Hossain A, Ahsan A, Monalisa NN, Rahman K, Azad SA. Moving Beyond Cancer: Immediate Impact on-the Health-Related Quality of Life of Breast Cancer Patients After Mastectomy. Bangladesh Med Res Counc Bull. 2015;41(2):52–8. Located at: rayyan-1124871447. doi:10.3329/bmrcb.v41i2.29974

59.   Villar RR, Fernández SP, Garea CC, Pillado MTS, Barreiro VB, Martín CG. Quality of life and anxiety in women with breast cancer before and after treatment. Rev Lat Am Enferm. 2017;25:e2958. Located at: rayyan-1124871322. doi:10.1590/1518-8345.2258.2958

60.   Gadisa DA, Wang SH, Yimer G. The Impact of AC and AC-T Chemotherapy's Toxicities on Quality of Life Among Women with Breast Cancer in Ethiopia: A Prospective Patient-Reported Outcomes Study. Breast Cancer Dove Med Press. 2021/03/05 ed. 2021;13:107–32. Located at: 33658844. doi:10.2147/bctt.S289014

61.   Fonseca S, Lencastre L, Guerra M. Life satisfaction in women with breast cancer. Paidéia. 2014;24(59):295–303. Located at: rayyan-1124871326. doi:10.1590/1982-43272459201403

62.   Jendrian S, Steffens K, Schmalfeldt B, Laakmann E, Bergelt C, Witzel I. Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience. Breast Cancer Res Treat. 2017;163(3):517–26. Located at: rayyan-1124869107. doi:10.1007/s10549-017-4208-6

63.   Shekhar N, Jaiswal R, Joseph L, Jain S, Jain S, Kr A, et al. An Overview of Psychological Analysis of Breast Cancer Patients undergoing Modified Radical Mastectomy and Breast Conservation Surgery and its impact on Objectified Body Consciousness at a Tertiary Care Cancer Centre in South India. Clin Breast Cancer. 20230607th ed. 2023 Oct;23(7):e394–400. Located at: 37400311. doi:10.1016/j.clbc.2023.05.017

64.   Yamani Ardakani B, Tirgari B, Roudi Rashtabadi O. Body image and its relationship with coping strategies: The views of Iranian breast cancer women following surgery. Eur J Cancer Care (Engl). 2020;29(1):N.PAG-N.PAG. Located at: rayyan-1124870635. doi:10.1111/ecc.13191

65.   Dubashi B, Vidhubala E, Cyriac S, Sagar TG. Quality of life among younger women with breast cancer: study from a tertiary cancer institute in south India. Indian J Cancer. 2010/05/08 ed. 2010 Apr;47(2):142–7. Located at: 20448376. doi:10.4103/0019-509x.63005

66.   Jankowska-Polanska B, Swiatoniowska-Lonc N, Osmialowska E, Galka A, Chabowski M. The Association Between Illness Acceptance and Quality of Life in Women with Breast Cancer. Cancer Manag Res. 2020;12:8451–64. Located at: rayyan-1124871352. doi:10.2147/cmar.S261624

67.   Jayasinghe R, Fernando A, Jayarajah U, Seneviratne S. Post treatment quality of life among Sri Lankan women with breast cancer. BMC Cancer. 2021/03/25 ed. 2021 Mar 23;21(1):305. Located at: 33757446. doi:10.1186/s12885-021-08055-5

68.   King MT, Kenny P, Shiell A, Hall J, Boyages J. Quality of life three months and one year after first treatment for early stage breast cancer: Influence of treatment and patient characteristics. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2000;9(7):789–800. Located at: rayyan-1124869882. doi:10.1023/A:1008936830764

69.   Konieczny M, Fal A. The Influence of the Surgical Treatment Method on the Quality of Life of Women With Breast Cancer. Eur J Breast Health. 2023;19(2):121–7. Located at: rayyan-1124871630. doi:10.4274/ejbh.galenos.2023.2022-9-1

70.   Mock VL. Body image in women treated for breast cancer [Internet]. Vol. 48. ProQuest Information & Learning; 1988. Located at: rayyan-1124868359. Available from: https://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1989-50875-001&site=ehost-live

71.   Munshi A, Dutta D, Kakkar S, Budrukkar A, Jalali R, Sarin R, et al. Comparison of early quality of life in patients treated with radiotherapy following mastectomy or breast conservation therapy: A prospective study. Radiother Oncol. 2010 Nov;97(2):288–93. Located at: WOS:000284812800022. doi:10.1016/j.radonc.2010.04.008

72.   Afshar-Bakshloo M, Albers S, Richter C, Berninger O, Blohmer JU, Roehle R, et al. How breast cancer therapies impact body image - real-world data from a prospective cohort study collecting patient-reported outcomes. BMC Cancer. 2023 Jul 28;23(1):705. doi:10.1186/s12885-023-11172-y PubMed PMID: 37507687; PubMed Central PMCID: PMC10375629.

73.   Moreira H, Canavarro MC. A longitudinal study about the body image and psychosocial adjustment of breast cancer patients during the course of the disease. Eur J Oncol Nurs. 2010;14(4):263–70. Located at: rayyan-1124869501. doi:10.1016/j.ejon.2010.04.001

74.   Cernikova KA, Kracmarova LK, Pesoutova M, Tavel P. We will be different forever: A qualitative study of changes of body image in women with breast cancer. BMC Public Health. 2024 Sep 16;24(1):2517. doi:10.1186/s12889-024-20017-7

75.   Anne Thamar Louis L, Fortin J, Roy CA, Brunet A, Aimé A. Body image interventions within breast cancer care: A systematic review and concept analysis. J Psychosoc Oncol. 2024 May 3;42(3):427–47. doi:10.1080/07347332.2023.2249879

76.   Lewis-Smith H, Diedrichs PC, Harcourt D. A pilot study of a body image intervention for breast cancer survivors. Body Image. 2018;27:21–31. Located at: cin20; 132940744. Language: English. Entry Date: 20181114. Revision Date: 20181121. Publication Type: Journal Article. doi:10.1016/j.bodyim.2018.08.006

77.   Bakhshi S. Women´s body image and the role of culture: A review of the literature. Eur J Psychol. 2011 May 30;7(2):2. doi:10.5964/ejop.v7i2.135

78.   Thorne SE, Murray C. Social constructions of breast cancer. Health Care Women Int. 2000;21(3):141–59. Located at: cin20; 107107747. Language: English. Entry Date: 20050712. Revision Date: 20231015. Publication Type: Journal Article. Journal Subset: Blind Peer Reviewed. doi:10.1080/073993300245221

79.   Yoo JJ, Carriveau K, Tran A, Shah M, Langlais M. A scoping review on cancer and body image research. Discov Psychol. 2024 Oct 23;4(1):147. doi:10.1007/s44202-024-00251-1

80.   Abdoli M, Scotto Rosato M, Desousa A, Cotrufo P. Cultural Differences in Body Image: A Systematic Review. Soc Sci. 2024 Jun 5;13(6):305. doi:10.3390/socsci13060305

81.   Erbil N. Attitudes towards menopause and depression, body image of women during menopause. Alex J Med. 2018 Sep 1;54(3):241–6. doi:10.1016/j.ajme.2017.05.012

82.   Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updat Surg. 2017 Sep;69(3):313–7. doi:10.1007/s13304-017-0424-1 PubMed PMID: 28260181.

83.   Johnson SM. Fears about breast cancer recurrence - Interviews with a diverse sample. Cancer Pract. 2001 Sep;9(5):237–43. Located at: WOS:000171022100005. doi:10.1046/j.1523-5394.2001.009005237.x

84.   Mathur P, Nath A, K SK. Adolescent and young adult cancers in India–Findings from the National Cancer Registry Programme. Cancer Epidemiol. 2022 Jun 1;78:102124. doi:10.1016/j.canep.2022.102124

85.   Montazeri A. Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008 Aug;27. Located at: WOS:000263459900001. doi:10.1186/1756-9966-27-32

86.   Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Ann Oncol. 20141208th ed. 2015 Apr;26(4):675–82. Located at: 25488686. doi:10.1093/annonc/mdu564

87.   Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989 Mar 30;320(13):822–8. doi:10.1056/NEJM198903303201302 PubMed PMID: 2927449.

88.   Jankowska M. A unique challenge: Sexuality in young women after breast cancer treatment from a developmental perspective. Eur J Cancer. 2014 Mar;50:S90–S90. Located at: WOS:000335106700184

89.   Baxter NN, Goodwin PJ, McLeod RS, Dion R, Devins G, Bombardier C. Reliability and validity of the body image after breast cancer questionnaire. Breast J. 2006/05/11 ed. 2006 May;12(3):221–32. Located at: 16684320. doi:10.1111/j.1075-122X.2006.00246.x

90.   Härtl K, Janni W, Kästner R, Sommer H, Strobl B, Rack B, et al. Impact of medical and demographic factors on long-term quality of life and body image of breast cancer patients. Ann Oncol. 2003 Jul;14(7):1064–71. Located at: WOS:000184382400015. doi:10.1093/annonc/mdg289

91.   Bartelink H, Dam FV, Dongen JV. Psychological effects of breast conserving therapy in comparison with radical mastectomy. Int J Radiat Oncol. 1985 Feb 1;11(2):381–5. doi:10.1016/0360-3016(85)90161-0

92.   Engel J, Kerr J, Schlesinger-Raab A, Sauer H, Hölzel D. Quality of Life Following Breast-Conserving Therapy or Mastectomy: Results of a 5-Year Prospective Study. Breast J. 2004;10(3):223–31. doi:10.1111/j.1075-122X.2004.21323.x

93.   Fobair P, Stewart SL, Chang S, D'Onofrio C, Banks PJ, Bloom JR. Body image and sexual problems in young women with breast cancer. Psychooncology. 2006 Jul;15(7):579–94. doi:10.1002/pon.991

94.	Tunç E, Orak OS, İşeri Ö. The Effect of Acceptance and Commitment Therapy--Based Psychoeducation on Body Image, Quality of Sexual Life, and Dyadic Adjustment of Women After Breast Cancer Surgery. Oncol Nurs Forum. 2023;50(5):599–609. Located at: cin20; 170059437. Language: English. Entry Date: 20230830. Revision Date: 20230830. Publication Type: Journal Article. doi:10.1188/23.ONF.599-609

95.	Younis M, Norsa'adah B, Othman A. Effectiveness of Psycho-Education Intervention Programme on Coping Strategies Among Jordanian Women Diagnosed with Breast Cancer: A Randomised Controlled Trial. Breast Cancer Targets Ther. 2021 May 11;13:285–97. doi:10.2147/BCTT.S299584

96.	Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. Eur J Cancer. 2001 Jan 1;37(2):189–97. doi:10.1016/S0959-8049(00)00353-1

97.	Polivy J. PSYCHOLOGICAL EFFECTS OF MASTECTOMY ON A WOMAN'S FEMININE SELF-CONCEPT. J Nerv Ment Dis. 1977 Feb;164(2):77.

98.	Cash TF. Multidimensional Body-Self Relations Questionnaire. 1990. doi:10.1037/t08755-000

99.	Littleton HL, Axsom D, Pury CLS. Development of the body image concern inventory. Behav Res Ther. 2005 Feb 1;43(2):229–41. doi:10.1016/j.brat.2003.12.006

100.	Probst M, Vandereycken W, Coppenolle HV, Vanderlinden J. The Body Attitude Test for Patients with an Eating Disorder: Psychometric Characteristics of a New Questionnaire. Eat Disord. 1995 Jan 1;3(2):133–44. doi:10.1080/10640269508249156

101.	Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996 Oct;14(10):2756–68. doi:10.1200/JCO.1996.14.10.2756

102.	McKinley NM, Hyde JS. The Objectified Body Consciousness Scale: Development and Validation. Psychol Women Q. 1996 Jun 1;20(2):181–215. doi:10.1111/j.1471-6402.1996.tb00467.x

103.	Veronesi U, von Kleist S, Redmond K, Costa A, Delvaux N, Freilich G, et al. Caring about women and cancer (CAWAC): a European survey of the perspectives and experiences of women with female cancers. Eur J Oncol Nurs. 1999 Dec 1;3(4):240–50. doi:10.1016/S1462-3889(99)81337-4

104.	Berscheid E, Walster E, Bohrnstedt G. The happy American body: A survey report. 1973. doi:10.1037/e400542009-006

105.	Kenny P, King MT, Shiell A, Seymour J, Boyages J, Hall J. Quality of life three months and one year after treatment for early stage breast cancer: discussion paper 42. Qual Life Three Mon One Year Treat Early Stage Breast Cancer. 2000.

106.	Machover K. Personality projection in the drawing of the human figure (A method of personality investigation). In: Personality projection in the drawing of the human figure: A method of personality investigation. Springfield, IL, US: Charles C Thomas Publisher; 1949. p. 3–32. (American lectures in psychology). doi:10.1037/11147-001

Table 1: Characteristics of included studies investigating body image (BI) in female with breast cancer (BCP) and healthy controls (HC).

Study	CO	BCP					HC			Matched by age	BI Qu.	Quality of study
		N	Age (mean/range)	BI score, mean (SD)	Tumor size/ Cancer stage	Treatment	N	Age (mean/range)	BI score, mean (SD)			
Aerts et al., 2014	BE	56	57/ 34-75	10.54 (8.17)	na/ Early BC stage	Surgery, Chemotherapy, Radiation therapy, Endocrine therapy	81	56/ 26-80	4.49 (5.04)	Yes	BIS	NOS: 7
Kraus, 1999	USA	31	52/ 29-82	122.94 (3.33)	na/ Early BC stage	Surgery	30	53/ 29-82	116.47 (3.30)	na	BIS*	NOS: 4
Montañés Muro et al., 2023	SPA	27	54/ 38-70	0.78 (0.44)	na/ na	Surgery	27	50/ 37-62	0.50 (0.27)	na	BIS	NOS: 7
Savani et al., 2023	IND	60	46/ na	10.48 (9.23)	na/ na	na	60	46/ na	1.60 (2.49)	Yes	BIS	NOS: 7
Jahromi et al., 2022	IRI	111	48/ 30-55	51.56 (15.09)	Cancer grade 2	Chemotherapy, Radiotherapy, Surgery	111	47/ 30-55	45.80 (16.82)	Yes	FOBIQ	NOS: 8
*Bagheri & Mazaheri, 2015	IRI	50	32/ na	109.94 (19.01)	na/ na	Radiotherapy	50	33/ X	120.20 (19.82)	na	MBSRQ	NOS: 7

Study	CO	N	Age M/SD			Treatment	N	Age M/SD			BI QU	NOS
*Jablonski et al., 2018	PL	39	55/ 34-68	na	na	Surgery, BCT	39	52/ 34-68	na	na	BS-Q	NOS:7
*Izdorczyk et al., 2018	PL	120	55/ na.	na	na	Mastectomy	99	54/ n.a.	na	Yes	BAQ	NOS:4
*Anagnostopolous & Myrgianni, 2009	GR	70	na	na	na	Surgery, Chemotherapy, Endocrine therapy, Radiotherapy	70	n.a.	na	na	BIS	NOS:7

Note. SD: Standard deviation; BIS: Body Image Scale (96); BIS*: Body Image Scale- Modified version (97); MBSRQ: Multidimensional Body-Self Relations Questionnaire (98); FOBIQ; Fear of Body Image Questionnaire (99); BS-Q: Body self-questionnaire (Mirucka, 2017); BAQ: Body Attitude Questionnaire (100) ; na.: Missing data; NOS: Newcastle-Ottawa scale. BCT: Breast conservative therapy; BI QU: Body Image related questionnaires; *: Studies in only Qualitative analysis; CO: Country; GR: Greece; PL:Poland; IRI: Iran; SPA: Spain; BE: Belgium; IND: India.

Table 2: Characteristics of included studies investigating body image (BI) in baseline and during treatment females with breast cancer (BC).

Study	CO	Before treatment		During treatment		Age (mean/ range)	Tumor size/ cancer stage	Treatment	BI QU	Quality of study
		N	BI score, mean (SD)	N	BI score, mean (SD)					
Aerts et al., 2014	BE	81	1.53 (3.48)	66	4.05 (5.52)	57/ 34-75	na./ Early stage BC	Surgery, Chemotherapy, Radiotherapy, Endocrine therapy	EORTC QOL-BR23	NOS: 6
Bueno et al., 2018	BR	166	84.50 (23.40)	166	80.60 (26.80)	59/ na	na./ na	Surgery	EORTC QOL-BR23	NOS: 4
Browall et al., 2008	SE	75	90.00 (18.00)	65	66.00 (30.00)	64/ 55-80	na./ Stage I: 23 Other stages: 52	Chemotherapy, Radiotherapy, Endocrine therapy, Surgery	EORTC QOL-BR23	NOS: 6
Rahman et al., 2015	BD	250	86.00 (7.83)	250	70.46 (6.36)	44/ 21-67	T1: 15 T2: 102 T3: 53 T4: 80/ na.	Mastectomy, Neoadjuvant chemotherapy	EORTC QOL-BR23	NOS: 8

Study	Country	N	Mean (SD)	N	Mean (SD)	Age/range	Stage	Treatment	Instrument	Quality
Viller et al., 2017	SPA	180	94.20 (13.20)	180	85.10 (23.00)	58/ na	na./ 0 : 22 I : 149 II : 128 III : 35 IV: 2	Chemotherapy, Radiotherapy, Hormone therapy, Biological therapy anti-Her2	EORTC QOL-BR23	NOS: 8
Binotto et al., 2020	BR	33	90.66 (14.99)	33	66.41 (31.49)	51/ na.	na./ Stage 1, 2 and 3	Surgery, Adjuvant or Neoadjuvant Taxane-based chemotherapy	EORTC QOL-BR23	NOS: 6
Castro e Silva et al., 2021	BR	80	25.73 (18.57)	80	34.06 (6.10)	52/ X	na./ Any at stage	Surgery, Chemotherapy	EORTC QOL-BR23	NOS: 5
Bahar et al., 2023	TUR	259	87.00 (18.00)	197	94.00 (13)	51/ 24-84	na./ I: 95 II: 156 III: 206	Radiotherapy, Surgery, Chemotherapy, Hormone therapy	EORTC QOL-BR23	NOS: 5
El Haidari et al., 2023	LB	120	89.20 (17.70)	116	81.00 (21.60)	54/ na.	T1: 42 T2: 71 missing: 7/ I: 52 II: 68	Surgery	EORTC QOL-BR23	NOS: 5
*Parker et al., 2007	USA	104	23.80 (5.50)	104	22.60 (6.10)	53/ na	na./ stage I and II	Chemotherapy, Radiotherapy, Surgery	EORTC QOL-BR23	NOS: 8

Study	CO	N	Age M (SD)	BI QU N		Age M/range	Stage	Treatment	Measure	Quality
*Gadisa et al., 2021	ET	146	na	na	na	42/ na	I: 6 II: 48 III: 64 IV: 28	Chemotherapy	EORTC QOL-BR23	NOS: 7
*Laroche et al., 2017	FR	109	66.00 (33)	109	na	61/ na.	Early stage BC	Surgery, Chemotherapy, Aromatase inhibitor	EORTC QOL-BR23	NOS: 4
*Carver et al., 1998	USA	66	na	61	na	52/ 28-76	I: 49 II: 17	Surgery, Chemotherapy, Hormone therapy, Radiotherapy	MBA	NOS: 3
*Metcalfe et al., 2012	CA	24	na	24	na	53/ 30-83	0: 19 I: 26 II: 41 III: 14	Surgery, Radiotherapy	BIBC	NOS: 5

Note. SD: Standard deviation; BIS: Body Image Scale (96) ; BIS*: Body Image Scale- Modified version (97);   EORT QoL-BR 23: European Organization for Research and Treatment of Cancer quality of life in patients with breast cancer (101); BIBC: Body image after breast cancer (Baxter, 1997); MBA: Measure of Body Apperception (30); NOS: Newcastle-Ottawa scale; na.: Missing data, BI QU: Body Image related questionnaires; *: Studies in only Qualitative analysis; CO: Country ; CA: Canada; FR: France; ET: Ethiopia; LB: Lebanon; TUR: Turkey; BR: Brazil; SPA: Spain; BE: Belgium; BD: Bangladesh; SE: Sweden.

Table 3: Characteristics of included studies investigating body image (BI) in females with breast cancer (BCP) treated with breast-conserving therapy (BCT) and mastectomy (MX).

Study	CO	BCP with BCT				BCP with MX				Age (mean / range)	BI QU	Quality of study
		N	BI score mean (SD)	Tumor size/ Cancer stage	Treatment	N	BI score mean (SD)	Tumor size/ Cancer stage	Treatment			
[a]Jendrian et al., 2017	GER	46	6.84 (6.30)	Tis/T1: 36 T2/T3/T4: 5	Surgery, Chemotherapy, Endocrine therapy	61	11.51 (7.67)	Tis/T1: 44 T2/T3/T4: 12	Surgery, Chemotherapy, Endocrine therapy	68/ 36.4-83.8	BIS	NOS: 6
[b]Jayasinghe et al., 2021	SL	19	58.35 (55.39)	T1: 15 T2: 27 T3 :5 T4 :2	Surgery, Adjuvant Chemotherapy, Hormone therapy, Adjuvant Radiotherapy, Axillary surgery	35	62.51 (27.68)	T1: 15 T2: 27 T3: 5 T4: 2	Surgery, Chemotherapy, Hormone therapy, Radiotherapy, Axillary surgery	58/ 36-81	EORT QoL-BR 23	ROBINS-I: MODERATE
[b]Munshi et al., 2010	IND	142	77.70 (21.80)	Early BC: 119 Advanced BC: 23	Adjuvant radiotherapy, Surgery	113	79.80 (35.20)	Early BC: 51 Advanced BC: 62	Adjuvant radiotherapy, Surgery	na	EORT QoL-BR 23	ROBINS-I: LOW

Study	Country	N	Mean (SD)	Stage	Treatment	N	Mean (SD)	Stage	Treatment		Measure	Quality
[b]King et al., 2000	AU	261	71.00 (15.00)	T1 and T2 (no exact number)/ Early stage of BC	Surgery, Radiotherapy, Chemotherapy	43	48 (28)	T1 and T2 (na)/ Early stage of BC	Surgery, Radiotherapy, Chemotherapy	BCT:54 /25-81 MX:53	ESBC	NOS: 5
[b]Konieczny and Fal, 2023	PL	125	58.97 (32.22)	na.	Surgery, Radiotherapy, Chemotherapy, Hormonal therapy, Systemic therapy	64	58.73 (31.16)	na.	Surgery, Radiotherapy, Chemotherapy, Hormonal therapy, Systemic therapy	55/ na.	EORT QoL-BR 23	ROBINS-I: LOW
[b]Dubashi et al., 2010	IND	18	76.88 (33.03)	T1: 2 T2: 31 T3: 18	Surgery, Chemotherapy, Hormonal therapy, Bilateral salpingo-oopherectomy	33	82.38 (26.20)	T1: 2 T2: 31 T3: 18	Surgery, Chemotherapy, Hormonal therapy, Bilateral salpingo-oopherectomy	30/ na.	EORT QoL-BR 23	ROBINS-I: LOW
[b]Mock, 1988	USA	90	97.20 (12.31)	Early BC stage	Surgery, Adjuvant chemotherapy	62	98.20 (12.47)	Early BC stage	Surgery, Adjuvant chemotherapy	52/ 29-79	BIS	NOS: 4
[b]Jankowska-Polańska et al., 2020	PL	50	74.50 (24.99)	na./ na	Surgery, Radiotherapy, Chemotherapy, Hormonal therapy	50	57.39 (24.25)	na./ na	Surgery, Radiotherapy, Chemotherapy, Hormonal therapy	53/ na	EORT QoL-BR 23	ROBINS-I: LOW

Study	Country	N	Mean (SD)	T-stage	Treatment	N	Mean (SD)	T-stage	Treatment	Age/range	Measure	Quality
[a]Ardakani et al., 2020	IRI	109	12.87 (6.41)	T1: 10 T2: 11 T3: 8 T4: 11 na: 140 na	Surgery, Radiotherapy, Chemotherapy, Hormonal therapy	71	15.18 (6.51)	T1: 10 T2: 11 T3: 8 T4: 11 na: 140 na	Surgery, Radiotherapy, Chemotherapy, Hormonal therapy	46/ 25-70	BIS	ROBINS-I: LOW
[a]Fonseca et al., 2014	PRT	26	3.69	na./ na	Surgery, Neoadjuvant chemotherapy	29	8.24 (7.22)	na./ na	Surgery, Neoadjuvant chemotherapy	54/ 32-79	BIS	ROBINS-I: MODERATE
[a]Aerts et al., 2014	BE	81	1.53 (3.48)	na./ na.	Surgery, Radiotherapy, Chemotherapy, Hormonal therapy	68	6.99 (7.58)	na./ na.	Surgery, Radiotherapy, Chemotherapy, Hormonal therapy	BCT: 57/ 34-75 MX: 54/ 26-74	BIS	NOS: 7
Montañés -Muro et al., 2023	SPA	13	0.64 (0.38)	na./ na	Surgery	14	0.91 (0.47)	na./ na.	Surgery	53/ 38-70	BIS	NOS: 7
[b]Parker et al., 2007	USA	104	23.6 (6.90)	na./ Stage I and II BC	Chemotherapy, Radiotherapy, Surgery	45	22.50 (5.10)	na./ Stage I and II BC	Chemotherapy, Radiotherapy, Surgery	BCT : 53 MX: 52/ na	MBSRQ	NOS: 8

Study	Country	N	Mean (SD)	Tumor stage	Treatment	N	Mean (SD)	Tumor stage	Treatment	Age	Measure	ROBINS-I
[a]Shekhar et al., 2023	IND	402	2.78 (3.67)	T1: 215 T2: 187/ 0: 10 1: 72 2: 253 3: 34	Hormone therapy, Radiotherapy, Surgery	304	29.38 (11.55)	T2: 148 T3: 156/ 0: 24 3: 280	Hormone therapy, Radiotherapy, Surgery	< 35 : 28 35-55: 362 55-70: 266 >70: 50	OBC	ROBINS-I: LOW
*Spatuzzi et al.,2016	ITA	72	na	BC stage 1-2	Surgery, Chemotherapy, Radiotherapy, Hormone therapy	44	na	BC stage 1 & 2	Surgery, Chemotherapy, Radiotherapy, Hormone therapy	BCT mean: 57 MX mean: 61.3	EORT QoL-BR 23	ROBINS-I: LOW
*Arican Alicikus et al., 2009	TUR	61	na	na	Surgery, Chemotherapy, Radiotherapy, Hormone therapy	51	na	na	Surgery, Chemotherapy, Radiotherapy, Hormone therapy	50/ 31-65	MBSRQ	ROBINS-I: LOW
*Yilmazer et al., 1994	TUR	40	na	BC stage 1& 2	Surgery, Chemotherapy, Radiotherapy	40	na	BC stage 1 and 2	Surgery, Chemotherapy, Radiotherapy	BCT: 40/ 27-50 MX: 43/ 30-50	A draw a person test	ROBINS-I: MODERATE

Study	Country	n	na	T stage	Treatment	n	na	T stage	Treatment	Mean/range	Measure	Quality
*Fung et al., 2001	CHN	17	na	Tis:1 T1:10 T2:6	Surgery	15	na	Tis:1 T1: 4 T2:!0	Surgery	BCT: 47 /na MX: 50 /na	Adopted initially the body image index	ROBINS-I: LOW
*Schou et al., 2005	NOR	85	na	Tis:2 T1:68 T2:30	Systematic therapy, Surgery, Radiotherapy	66	na	Tis:2 T1:68 T2:30	Systematic therapy, Surgery, Radiotherapy	56/ 21-78	CAWAC	ROBINS-I: LOW
*Yurek et al., 2000	USA	78	na	T2: 165 T3: 25	Surgery, Adjuvant therapy	79	na	T2: 165 T3: 25	Surgery, Adjuvant therapy	51/ 30-84	BSS	ROBINS-I: LOW
*Arikan et al., 2020	TUR	52	na	T1:9 T2: 71 T3: 19 T4: 18	Surgery, Chemotherapy, Target therapy, Hormone therapy	58	na	T1:9 T2: 71 T3: 19 T4: 18	Surgery, Chemotherapy, Target therapy, Hormone therapy	56/ 27-91	BIS	ROBINS-I: LOW
*Afshar-Bakshloo et al.,2023	GER	212	Na	T0: 161 T1: 48	Surgery, Chemotherapy, Target therapy, Radiotherapy	27	Na	T0: 27	Surgery, Chemotherapy, Target therapy, Radiotherapy		EORT QoL-BR 23	ROBINS-I: MODERATE
*Kraus, 1999	USA	16	na	Early BC	na	15	na	Early BC	Surgery	52/ 29-82	BIS*	NOS: 4

Note. BIS: Body Image Scale (96) ; BIS*: Body Image Scale- Modified version (97);   OBC: Objectified body consciousness (102); MBSRQ: Multidimensional Body-Self relations questionnaire (98) ; EORT QoL-BR 23: European Organization for Research and Treatment of Cancer quality of life in patients with breast cancer (101); CAWAC: Caring about women and cancer (103);

BSS: Body satisfaction scale (104) ; ESBC: Enhanced Body Image Scale for Breast Cancer (105); A draw a person test (106); Adopted initially the body image index (Lasry et al., 1987) ; n.a.: Missing data; NOS: Newcastle-Ottawa scale; ROBINS-I: Risk Of Bias In Non-randomised Studies - of Interventions, BI QU: Body Image related questionnaires; [a]: Negative direction; [b]: Positive direction; *: Studies in only Qualitative analysis; CO: Country; GER: Germany; NOR: Norway; BE: Belgium, IRI: Iran; CHN: China; ITA: Italy; IND: India; SPA: Spain; PRT: Portugal; PL:Poland; SL:Sri Lanka; TUR; Turkey, AU: Australia.